Current Research: Medical Oncology

C80405 -- Irinotecan/5-FU/Leucovorin (FOLFIRI) or Oxaliplatin/5-FU/Leucovorin (FOLFOX) with Bevacizumab, or Cetuximab, or Combination of Bevacizumab and Cetuximab for Metastatic Adenocarcinoma of the Colon or Rectum

This study is comparing three Arms:

• Arm A, Bevacizumab every 2 weeks followed by FOLFOX or FOLFIRI every 2 weeks
• Arm B, Cetuximab weekly followed by FOLFOX or FOLFIRI every 2 weeks
• Arm C, Cetuximab weekly, followed by Bevacizumab every 2 weeks, followed by FOLFOX or FOLFIRI every 2 weeks

Eligibility

You may be eligible for this trial if:

• You have histologically or cytologically documented locally advanced or metastatic colorectal cancer.
• You have no prior treatment for advanced or metastatic colorectal cancer
  • No prior radiotherapy to >25% of bone marrow
  • > 4 weeks since major surgery
• You have no previous or concurrent malignancy
• You have no known central nervous system metastases or carcinomatous meningitis
• You are not pregnant or nursing
• You are at least 18 years old

Trial Sponsor

• Cancer and Leukemia Group B (CALGB)

Project Begin Date

• Oct 2006

Tentative Project End Date

• Sept 2011

Back to Medical Oncology Research

Revised March 30, 2009.   Please send comments, suggestions or questions about this page to Goldei Posey, gposey@mcg.edu .